mci 154 has been researched along with Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Tombe, P; Doye, A; Gwathmey, JK; Ito, T; Li, X; Liao, R; Okafor, C; Perreault-Micale, C; Stepanek, A | 1 |
| Abe, Y; Ishibashi, A; Kawasumi, H; Kitada, Y | 1 |
2 other study(ies) available for mci 154 and Cardiomyopathies
| Article | Year |
|---|---|
Mg-ATPase and Ca+ activated myosin AtPase activity in ventricular myofibrils from non-failing and diseased human hearts--effects of calcium sensitizing agents MCI-154, DPI 201-106, and caffeine.
Topics: Ca(2+) Mg(2+)-ATPase; Caffeine; Calcium; Cardiomyopathies; Cardiotonic Agents; Heart; Heart Ventricles; Humans; Myocardium; Myofibrils; Myosins; Piperazines; Pyridazines | 2003 |
MCI-154, a Ca2+ sensitizer, increases survival in cardiomyopathic hamsters.
Topics: Animals; Calcium; Cardiomyopathies; Cardiotonic Agents; Cricetinae; Disease Models, Animal; Male; Mesocricetus; Pyridazines | 1999 |